A PHASE II TRIAL OF ERLOTINIB VERSUS PEMETREXED AS SECOND-LINE THERAPY IN TREATING PATIENTS WITH ADVANCED EGFR WILD-TYPE AND EGFR FISH-POSITIVE LUNG ADENOCARCINOMA
JOURNAL OF THORACIC ONCOLOGY（2013）
关键词
non-small cell lung cancer,second-line
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要